Treatment of melasma

被引:148
作者
Rendon, M
Berneburg, M
Arellano, I
Picardo, M
机构
[1] Dermatol & Aesthet Ctr, Boca Raton, FL 33486 USA
[2] Univ Tubingen, Dept Dermatol Phototherapy Lasermed PDT, Tubingen, Germany
[3] Mexico Gen Hosp, Dept Dermatol, Mexico City, DF, Mexico
[4] San Gallicano Dermatol Inst, Dept Cutaneous Physiopathol, Rome, Italy
关键词
D O I
10.1016/j.jaad.2005.12.039
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Treatment of melasma involves the use of a range of topical depigmenting agents and physical therapies. Varying degrees of success have been achieved with these therapies. The Pigmentary Disorders Academy (PDA) undertook to evaluate the clinical efficacy of the different treatments of melasma in order to generate a consensus statement on its management. Clinical papers published during the past 20 years were identified through MEDLINE searches and methodology and Outcome assessed according to guidelines adapted from the US Preventive Services Task Force (USPSTF). The consensus of the group was that first-line therapy for melasma should consist of effective topical therapies, mainly fixed triple combinations. Where patients have either sensitivity to the ingredients or a triple combination therapy is unavailable, other compounds with dual ingredients (hydroquinone plus glycolic acid) or single agents (4% hydroquinone, 0.1% retinoic acid, or 20% azelaic acid) may be considered as an alternative. In patients who failed to respond to therapy, options for second-line therapy include peels either alone or in combination with topical therapy. Some patients will require therapy to maintain remission status and a combination of topical therapies should be considered. Lasers Should rarely be Used in the treatment of melasma and, if applied, skin type should be taken into account.
引用
收藏
页码:S272 / S281
页数:10
相关论文
共 44 条
[1]
Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma:: Split-face design [J].
Angsuwarangsee, S ;
Polnikorn, N .
DERMATOLOGIC SURGERY, 2003, 29 (01) :59-64
[2]
THE TREATMENT OF MELASMA - 20-PERCENT AZELAIC ACID VERSUS 4-PERCENT HYDROQUINONE CREAM [J].
BALINA, LM ;
GRAUPE, K .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1991, 30 (12) :893-895
[3]
CESTARI TF, 2005, 63 ANN M AM AC DERM
[4]
The use of chemical peelings in the treatment of different cutaneous hyperpigmentations [J].
Cotellessa, C ;
Peris, K ;
Onorati, MT ;
Fargnoli, MC ;
Chimenti, S .
DERMATOLOGIC SURGERY, 1999, 25 (06) :450-454
[5]
Tretinoin peeling [J].
Cucé, LC ;
Bertino, MCM ;
Scattone, L ;
Birkenhauer, MC .
DERMATOLOGIC SURGERY, 2001, 27 (01) :12-14
[6]
Adapalene in the treatment of melasma: A preliminary report [J].
Dogra, S ;
Kanwar, AJ ;
Parsad, D .
JOURNAL OF DERMATOLOGY, 2002, 29 (08) :539-540
[7]
A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma [J].
Ennes, SBP ;
Paschoalick, RC ;
Alchorne, MMD .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2000, 11 (03) :173-179
[8]
AZELAIC ACID - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN ACNE AND HYPERPIGMENTARY SKIN DISORDERS [J].
FITTON, A ;
GOA, KL .
DRUGS, 1991, 41 (05) :780-798
[9]
The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions [J].
Garcia, A ;
Fulton, JE .
DERMATOLOGIC SURGERY, 1996, 22 (05) :443-447
[10]
TOPICAL TRETINOIN (RETINOIC ACID) IMPROVES MELASMA - A VEHICLE-CONTROLLED, CLINICAL-TRIAL [J].
GRIFFITHS, CEM ;
FINKEL, LJ ;
DITRE, CM ;
HAMILTON, TA ;
ELLIS, CN ;
VOORHEES, JJ .
BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (04) :415-421